136 related articles for article (PubMed ID: 8981527)
21. Effect of erythropoietin in continuous ambulatory peritoneal dialysis patients: comparison between intravenous and intraperitoneal administration.
Nasu T; Mitui H; Shinohara Y; Hayashida S; Ohtuka H
Perit Dial Int; 1992; 12(4):373-7. PubMed ID: 1420496
[TBL] [Abstract][Full Text] [Related]
22. Subcutaneous recombinant human erythropoietin in patients on CAPD.
Lye WC; Lee EJ
Adv Perit Dial; 1991; 7():285-7. PubMed ID: 1680447
[TBL] [Abstract][Full Text] [Related]
23. [Anemia in peritoneal dialysis patients].
Lausević M; Nesić V; Jovanović N; Stojimirović B
Srp Arh Celok Lek; 2006; 134(3-4):133-7. PubMed ID: 16915754
[TBL] [Abstract][Full Text] [Related]
24. Anemia of chronic renal failure: treatment with erythropoietin.
Navarro M; Alonso A; Avilla JM; Espinosa L
Child Nephrol Urol; 1991; 11(3):146-51. PubMed ID: 1777893
[TBL] [Abstract][Full Text] [Related]
25. Testing a single monthly dose of darbepoetin alpha to maintain hemoglobin levels in continuous ambulatory peritoneal dialysis patients.
Suzuki H; Inoue T; Watanabe Y; Kikuta T; Sato T; Tsuda M; Uchida K
Adv Perit Dial; 2011; 27():60-4. PubMed ID: 22073831
[TBL] [Abstract][Full Text] [Related]
26. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
27. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
28. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
29. Human erythropoietin in children undergoing continuous ambulatory peritoneal dialysis.
Hisano S; Kaku Y; Ueda K; Onoyama K
Acta Paediatr Jpn; 1992 Feb; 34(1):36-41. PubMed ID: 1580151
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
Lui SF; Chung WW; Leung CB; Chan K; Lai KN
Clin Nephrol; 1990 Jan; 33(1):47-51. PubMed ID: 2302870
[TBL] [Abstract][Full Text] [Related]
31. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of recombinant erythropoietin after subcutaneous or intraperitoneal administration to patients on CAPD.
Icardi A; Paoletti E; Molinelli G
Adv Perit Dial; 1990; 6():292-5. PubMed ID: 1982830
[TBL] [Abstract][Full Text] [Related]
33. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients.
Lui SF; Wong KC; Li PK; Lai KN
Am J Nephrol; 1992; 12(1-2):55-60. PubMed ID: 1415366
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study.
Albertazzi A; Di Liberato L; Daniele F; Battistel V; Colombi L
Int J Artif Organs; 1998 Jan; 21(1):12-8. PubMed ID: 9554820
[TBL] [Abstract][Full Text] [Related]
35. Once weekly subcutaneous erythropoietin is an effective maintenance therapy in the treatment of anemia of end stage renal disease in patients on CAPD.
Saleh A; Krane NK; Caballero M; Starks E
Adv Perit Dial; 1991; 7():288-91. PubMed ID: 1680448
[TBL] [Abstract][Full Text] [Related]
36. [Single weekly dose of recombinant erythropoietin in children with chronic renal insufficiency].
Guízar JM; Gutiérrez MJ; Sánchez G; Kornhauser C
Rev Invest Clin; 1996; 48(3):173-7. PubMed ID: 8966377
[TBL] [Abstract][Full Text] [Related]
37. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
[TBL] [Abstract][Full Text] [Related]
38. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
[TBL] [Abstract][Full Text] [Related]
39. The influence of l-carnitine supplementation on hematocrit and hemoglobin levels in patients with end stage renal failure on CAPD.
Sotirakopoulos N; Athanasiou G; Tsitsios T; Mavromatidis K
Ren Fail; 2002 Jul; 24(4):505-10. PubMed ID: 12212830
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients.
Parker KP; Mitch WE; Stivelman JC; Macon EJ; Bailey JL; Sands JM
J Am Soc Nephrol; 1997 Feb; 8(2):288-93. PubMed ID: 9048348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
